Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Ankri, Chen ^a   Cohen, Cyrille J ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Adoptive T cell transfer; CD28; Immunotherapy; PD1; T cell engineering

Indexed keywords

B7 DC PROTEIN; CD28 ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOKINE RELEASE; HUMAN; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MELANOMA; NONHUMAN; T LYMPHOCYTE; UPREGULATION;

EID: 84899081871     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27399     Document Type: Article

References (10)

1. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008; 14:550-9; PMID:18986838; http://dx.doi.org/10.1016/j.molmed.2008.09.010.
2. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672; http://dx.doi. org/10.1038/ni.2035.
3. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331.
4. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j. coi.2011.12.009.
5. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191.
6. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22:14-22; PMID:22210183; http://dx.doi.org/10.1016/j. semcancer.2011.12.006.
7. Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD. Restoration of CD28 expression in CD28-CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 2003; 198:947-55; PMID:12963692; http://dx.doi.org/10.1084/jem.20021288.
8. Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int J Cancer 2013; 133:2903-13; http://dx.doi.org/10.1002/ijc.28320; PMID:23754772.
9. Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol 2013; 191:4121-9; PMID:24026081; http://dx.doi.org/10.4049/jimmunol.1203085.
10. Shin JH, Park HB, Oh YM, Lim DP, Lee JE, Seo HH, Lee SJ, Eom HS, Kim IH, Lee SH, et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood 2012; 119:5678-87; PMID:22538857; http://dx.doi.org/10.1182/blood-2011-09-380519.